Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1993-8-24
|
| pubmed:abstractText |
A clinical trial of adoptive immunotherapy was carried out with peripheral blood lymphocytes (PBL), cocultured in vitro with autologous tumor cells and interleukin-2 (IL-2), in 14 patients with advanced melanoma. PBL from these patients were cocultured with irradiated autologous tumor cells for 7 days, which was followed by expansion in IL-2-containing medium. These lymphocytes were returned to the patient along with intravenous IL-2 at doses up to 2 x 10(6) IU m-2 day-1. A dose of 300 mg/m2 cyclophosphamide was administered to each patient intravenously 4 days prior to each treatment. Following coculture, the lymphocytes were primarily CD3+ T cells and they expressed varied degrees of cytotoxicity against autologous melanoma cells. In 9 patients the activated cells were at least 80% CD4+ and in 2 cases they were mostly CD8+. Some of the activated cells exhibited suppressor or helper activity in a functional regulatory coculture assay. No major therapeutic response was observed in this study. Minor responses were observed in 2 patients. Toxicities were those expected from the IL-2 dose administered.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0340-7004
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
175-80
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8392912-Adult,
pubmed-meshheading:8392912-Aged,
pubmed-meshheading:8392912-Cell Line,
pubmed-meshheading:8392912-Cyclophosphamide,
pubmed-meshheading:8392912-Cytotoxicity, Immunologic,
pubmed-meshheading:8392912-Female,
pubmed-meshheading:8392912-Gene Rearrangement, beta-Chain T-Cell Antigen Receptor,
pubmed-meshheading:8392912-Humans,
pubmed-meshheading:8392912-Immunophenotyping,
pubmed-meshheading:8392912-Immunotherapy, Adoptive,
pubmed-meshheading:8392912-Infusions, Intravenous,
pubmed-meshheading:8392912-Interleukin-2,
pubmed-meshheading:8392912-Lymphocytes,
pubmed-meshheading:8392912-Male,
pubmed-meshheading:8392912-Melanoma,
pubmed-meshheading:8392912-Middle Aged,
pubmed-meshheading:8392912-Receptors, Antigen, T-Cell, alpha-beta,
pubmed-meshheading:8392912-Tumor Cells, Cultured
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2.
|
| pubmed:affiliation |
Department of Medicine, University of Connecticut Health Center, Farmington 06030.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|